Stay updated with breaking news from Trials Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carlos Del Rio is Rollins Professor and chair of the Hubert Department of Global Health. He also co-directs the Emory Center for AIDS Research and leads the Emory AIDS International Training and Research Program (AITRP).
Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected...
The CAB-LA injection is the first of its kind in HIV prevention interventions and only needs to be taken every eight weeks
Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.
Approval marks pivotal expansion of HIV prevention options in the United States. Yesterday the U.S. Food and Drug Administration announced its first